( S )‐Pyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA‐MB‐468 Cells
ChemMedChem · 2026
DOI: 10.1002/cmdc.70463 ↗At a glance
Journal article in ChemMedChem, 2026. Written by Narges Hosseininasab and 10 co-authors. Institution: College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea. Major MEDLINE topics: Proto-Oncogene Proteins c-akt, Antineoplastic Agents, Pyrazines, Protein Kinase Inhibitors. 35 references. The full text is freely available (open access, CC BY 4.0). Funded by: Chungbuk National University, National Research Foundation of Korea, Korea government (MSIT).
Abstract (original language)
Triple‐negative breast cancer (TNBC) remains a major clinical challenge due to the absence of effective targeted therapies. In this study, thirty analogs of ( S )‐1‐oxo‐1,2,3,4‐tetrahydropyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide ( A1 – F5 ) were designed, synthesized, and evaluated for their cytotoxic activity against hormone receptor‐positive breast cancer (MCF‐7) and EGFR‐overexpressing TNBC (MDA‐MB‐468) cell lines. Notably, compounds B1 and B3 exhibited potent growth inhibition toward MDA‐MB‐468 cells, with GI 50 values of 2.8 and 4.7 µM, respectively, surpassing the efficacy of the reference compound ( Ref 2 , GI 50 : 7.6 µM) and gefitinib (GI 50 : 16.5 µM). Flow cytometric analysis demonstrated significant apoptosis induction by compounds B1 and B3 , with rates of 42.8% and 42.2%, respectively. Mechanistic investigations revealed that compounds B1 and B3 selectively inhibited Akt phosphorylation and enhanced JNK phosphorylation, suggesting a dual modulation of survival and apoptotic pathways. These findings support the development of N2 ‐benzyl‐( S )‐1‐oxo‐1,2,3,4‐tetrahydropyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide analogs, particularly compound B1 , as selective therapeutic candidates for triple‐negative breast cancer.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
- College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.
- Development Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation (KMEDIhub), Daegu, Republic of Korea.
ORCID profiles: Soonsil Hyun, Jae-Hwan Kwak
Funding
- Chungbuk National University
- National Research Foundation of Korea
- Korea government (MSIT)
Cite
APA
Hosseininasab, N., Kim, S. H., Kwon, Y. M., Park, J., Jung, C., Lee, K., Wi, B. J., Yoo, S. J., Hyun, S., Jung, Y. S., & Kwak, J. H. (2026). ( S )‐Pyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA‐MB‐468 Cells. ChemMedChem. https://doi.org/10.1002/cmdc.70463
Vancouver
Hosseininasab N, Kim SH, Kwon YM, Park J, Jung C, Lee K, et al. ( S )‐Pyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA‐MB‐468 Cells. ChemMedChem. 2026. doi:10.1002/cmdc.70463
BibTeX
@article{Hosseininasab2026,
author = {Hosseininasab, Narges and Kim, Sou Hyun and Kwon, Ye-Mi and Park, Jungjin and Jung, Chanhyun and Lee, Kwanghee and Wi, Beom-Jun and Yoo, Su-Jin and Hyun, Soonsil and Jung, Young-Suk and Kwak, Jae-Hwan},
title = {( S )‐Pyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA‐MB‐468 Cells},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70463}
}
EUVIMED